Corvus Pharmaceuticals, Inc.
Here’s whether Corvus Pharmaceuticals, Inc. (CRVS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +418.3%; 3-month momentum positive (+108.0%). Concerns: 50-day MA is falling (-7.82% over 10 days); RSI 71 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.75x 30d avg). Currently 37.9% off its 52-week high. Score: +2/7.
CRVS is in a confirmed uptrend, trading above both its 50-day ($16.26) and 200-day ($9.92) moving averages. With an RSI of 70.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +418.3% compares to +35.1% for SPY (beat the market by 383.2%). The current 37.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.